Forget whether progression-free survival (PFS) should be a surrogate endpoint in cancer trials, the FDA said as it charged the Oncologic Drug Advisory Committee (ODAC) Tuesday to look at reducing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback